Nisoldipine is an FDA-approved 1,4-dihydropyridine calcium-channel blocker for the management of hypertension. The drug may be used alone or in combination with other antihypertensive agents (i.e., Angiotensin-Converting Enzyme Inhibitors, diuretics, or beta-blockers). The medication is also safe and effective for use in the geriatric population. Off-label, nisoldipine may be used for the treatment of certain ischemic heart conditions such as stable angina or prinzmetal angina.
Mechanism of Action
Earn CME credit as you help guide your clinical decisions.
Nisoldipine falls under the class of dihydropyridine calcium channel blockers. The drug acts on the systemic smooth muscle cells by inhibiting the influx of calcium and by blocking the voltage-gated calcium channels located on the cells — the reduction in the calcium results in the dilation of coronary and systemic arteries. Nisoldipine exhibits both antihypertensive and anti-anginal activity due to its ability to reduce systemic blood pressure and the myocardial oxygen demand (thereby increasing myocardial oxygen delivery to cells). This action ultimately results in vasodilation and decreases peripheral vascular resistance.
Nisoldipine is metabolized in the liver via the CYP3A4 pathway and excreted through the renal pathway. It has a half-life of between 9 to 18 hours and a bioavailability of about 5%. The drug does not manifest any changes in the serum calcium concentrations and is insoluble in water.
Nisoldipine is available as an oral formulation as an extended-release tablet ( 20 mg, 30 mg, and 40 mg ) or as an extended-release hydrogel ( 8.5 mg, 17 mg, and 34 mg ). The patient should take the medication on an empty stomach or an hour after meals. The drug is to be swallowed whole with water and not crushed or divided. The dosing adjustment recommendations are on weekly intervals based on patient response. Avoid grapefruit juice and high-fat meals with the medication administration due to their effect on drug bioavailability.
- In adults: Extended-release hydrogel is started at 17 mg by mouth daily, and the maximum daily dose is 34 mg by mouth daily. It is increased by 8.5 mg every week or at longer intervals to achieve optimum blood pressure. The maintenance dose for nisoldipine ranges between 17 to 34 mg daily. In comparison, the original extended-release formulation is started at 20 mg per day up to the maximum dose of 40 mg daily. The dose is increased every two to four weeks to achieve optimum blood pressure control. Either of these formulations can be used in combination with ACE inhibitors, ARBs, beta-blockers, or thiazide diuretics if monotherapy is insufficient to attain the blood pressure goal.
- In the geriatric population: It is started at 8.5 mg orally each day.
For Ischemic Heart Conditions
- In adults: 8.5 to 34 mg of extended-release hydrogel formulation by mouth daily.
- In the geriatric population: 8.5 mg orally each day.
Patients with Hepatic Impairment
- 8.5 to 10 mg orally daily (do not exceed 30 mg daily)
Patients with Renal Impairment
- Because the pharmacokinetics of nisoldipine is not significantly different in patients with various degrees of renal impairment, dose adjustments are not required in patients with mild to moderate renal impairment.
However, drug safety and efficacy in the pediatric population, pregnant women, and breastfeeding women remain unestablished.
The equivalency of Nisoldipine dose is as follows.
|Original Extended-Release Formulation||10 mg||20 mg||30 mg||40 mg|
|Extended-Release Hydrogel (newer) Formulation||8.5 mg||17 mg||25.5 mg||34 mg|
Though nisoldipine is a well-tolerated medication among patients, it does have some side effects mainly associated with its vasodilating property. Common adverse effects associated with nisoldipine include flushing, vasodilation (4%), hypotension, syncope, peripheral edema (7% to 29% and it is dose-related), headache (22%), dizziness (3% to 10%), and nausea (2%). Additionally, chest pain (2%), palpitations (3%), dermatitis (2%), pharyngitis (5%), and sinusitis (3%) may also exhibit in individuals taking nisoldipine. Conditions such as anemia, anxiety, alopecia, difficulty swallowing, gingival hyperplasia, or ischemia are associated with less than 1% of the population taking the drug.
In less than 1 % population taking nisoldipine following adverse reactions are reported in postmarketing surveillance.
Abnormal hepatic function tests increased blood urea nitrogen, increased nonprotein nitrogen, increased creatine phosphokinase, increased serum creatinine, anorexia, hepatomegaly, abnormal dreams, amnesia, anxiety, ataxia, cerebral ischemia, cerebrovascular accident, depression, drowsiness, insomnia, abnormal T waves on ECG, ejection murmur (systolic), first-degree atrioventricular block, atrial fibrillation, myocardial infarction, cardiac failure (decompensated), supraventricular tachycardia amblyopia, blepharitis, diaphoresis, glaucoma, keratoconjunctivitis, exfoliative dermatitis, facial edema, alopecia, dermal ulcer, hypersensitivity reaction (e.g., chest tightness, hypotension, angioedema, shortness of breath, skin rash, and /or tachycardia), maculopapular rash, increased appetite, oral mucosa ulcer, anemia, hematuria, colitis, diarrhea, dysgeusia, dyspepsia, dysphagia, dysuria, epistaxis, gastritis, gastrointestinal hemorrhage, gingival hyperplasia, glossitis, leukopenia, malaise, melena, fever, flu-like symptoms, arthralgia, arthritis, gout, bruise, herpes simplex infection, herpes zoster, cellulitis, dyspnea, asthma, diabetes mellitus, hypertension, hypokalemia, hypotension, decreased libido, and gynecomastia are reported by manufacturer's product label.
Withdrawal Effects: Studies have shown that the abrupt withdrawal of nisoldipine may result in chest palpitations, chest pain, or increased severity of angina or hypertension. Thus the medication must be slowly tapered over time.
Nisoldipine is contraindicated in individuals with hypersensitivity to the drug or other dihydropyridine calcium channel blockers. Caution is necessary for the elderly population due to higher drug plasma concentrations; recommendations are to start at a lower dose for safety.
Breastfeeding women should avoid this drug due to the risk of excretion into breast milk. Due to the lack of well-controlled studies, pregnant women should avoid drug use to prevent any teratogenicity. Avoid concurrent use with cytochrome P450 inducers and inhibitors. Nisoldipine is also contraindicated with grapefruit products and high-fat meals (i.e., cheese, white bread, fried potatoes) due to its effect on absorption. Individuals diagnosed with GERD or a hiatal hernia should exercise caution when using nisoldipine due to its action on the esophageal sphincter.
Hypotension/syncope: Hypotension with or without syncope is rarely reported, and target blood pressure should be attained at a rate appropriate for the patient's clinical condition. Clinicians should closely monitor patients during initial dosing and at dosage titrations.
Peripheral Edema: The most common adverse reaction of nisoldipine is peripheral edema, which occurs within two to three weeks of therapy initiation.
Angina/ Myocardial Infarction: Extreme caution is necessary for patients with aortic stenosis, myocardial infarction, or hypotension due to the risk of reflex tachycardia resulting in the possible exacerbation of angina or worsening of myocardial infarction (MI), especially in the absence of concomitant beta-blockade. Though rare, patients with coronary artery disease may have increased frequency or severity of angina when starting nisoldipine. Safety measures are advised in patients with heart failure or left ventricular dysfunction and severe bradycardia due to the drug's hypotensive effect.
Heart failure (HF): According to ACC/AHA heart failure guidelines, calcium channel blockers, in general, should be avoided in patients with heart failure due to lack of benefit and/or worsening of outcomes.
Hepatic impairment: Use with caution in patients with severe hepatic impairment.
Individuals taking nisoldipine should undergo monitoring to relieve symptoms and any adverse effects pertaining to the medication. The patient's blood pressure should be carefully observed during each clinic visit and at home. It is also essential to monitor the cardiac function (i.e., heart rate) for any abnormalities at each physician visit and make dose adjustments accordingly. It is also crucial to taper the dose slowly and make adjustments at weekly intervals. Liver function (LFTs) monitoring is required in individuals with hepatic impairment. No dose adjustments are necessary for renal impairment.
The medication should be stored in a cool place, away from heat and moisture.
Toxicity due to nisoldipine has its basis in clinical status and history. As described above, hypotension, coupled with reflex tachycardia, can present when patients take an overdose on dihydropyridine calcium channel blockers such as nisoldipine. In some severe cases of nisoldipine toxicity, the clinician will note hypotension with bradycardia. Secondary findings of confusion, heart failure, and abnormal ECG changes such as PR prolongation can indicate toxicity. Additionally, hyperglycemia in patients without diabetes can suggest calcium channel blockers poisoning.
If toxicity is suspected, resuscitation is a priority. IV fluids and atropine for bradycardia are necessary alongside frequent reassessments by clinical staff. If a patient presents with severe symptoms, maintaining the airway, IV isotonic crystalloid, calcium salts, glucagon, insulin, and vasopressor therapy are all viable options and usable collectively. Activated charcoal should be administered in all patients suspected of nisoldipine overdose.
Enhancing Healthcare Team Outcomes
An interprofessional healthcare team is the optimal means to successfully manage patients treated with dihydropyridine calcium channel blockers such as nisoldipine. Providers must be knowledgeable regarding the symptoms of toxicity. A team consisting of nurses, laboratory technicians, pharmacists, physicians, and other healthcare professionals is necessary to optimize care to improve clinical outcomes in case of overdose. Pharmacists should offer to consult about the use of glucagon, insulin, and vasopressor therapy. A toxicologist consult should also take place when indicated. Cardiologists, intensivists, and the emergency team may have involvement in managing a patient further as many of these cases require further interventional management during the hospital course, including maintenance of an airway. By coordinating care, a patient on nisoldipine who may be experiencing toxicity or adverse symptoms can be successfully managed.
Interprofessional team dynamics will also serve to prevent nisoldipine adverse reactions. The prescriber can consult a pharmacist to verify dosing and check the medication record for potential drug interactions. Nursing will be able to perform much of the monitoring necessary at follow-up visits and help determine patient compliance and treatment effectiveness. Both the pharmacist and nursing should promptly alert the prescriber to any concerns, so adjustments to the regimen (either dosing or agent selection) can be made and lead to improved patient outcomes. [Level 5]
Langan J, Rodríguez-Mañas L, Sareli P, Heinig R. Nisoldipine CC: clinical experience in hypertension. Cardiology. 1997:88 Suppl 1():56-62; discussion 63-5 [PubMed PMID: 9118169]
Thadani U, Zellner SR, Glasser S, Bittar N, Montoro R, Miller AB, Chaitman B, Schulman P, Stahl A, DiBianco R. Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris. Circulation. 1991 Dec:84(6):2398-408 [PubMed PMID: 1959195]Level 2 (mid-level) evidence
Chen YH, Liu RC, Wang SP. Antianginal and anti-ischemic efficacy of nisoldipine in stable angina pectoris: a randomized, double-blind, placebo-controlled trial. Zhonghua yi xue za zhi = Chinese medical journal; Free China ed. 1996 Nov:58(5):323-8 [PubMed PMID: 9037847]Level 1 (high-level) evidence
Dudhipala N, Veerabrahma K. Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design. Drug development and industrial pharmacy. 2015:41(12):1968-77. doi: 10.3109/03639045.2015.1024685. Epub 2015 Apr 1 [PubMed PMID: 25830370]
Kim S, Yu YM, Kwon J, Yoo H, Jung SH, Lee E. Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review. International journal of environmental research and public health. 2019 Apr 13:16(8):. doi: 10.3390/ijerph16081333. Epub 2019 Apr 13 [PubMed PMID: 31013922]Level 1 (high-level) evidence
Dudhipala N, Janga KY, Gorre T. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation. Artificial cells, nanomedicine, and biotechnology. 2018:46(sup2):616-625. doi: 10.1080/21691401.2018.1465068. Epub 2018 Apr 24 [PubMed PMID: 29688077]Level 2 (mid-level) evidence
Rameis H. [Principles of the pharmacokinetics and pharmacodynamics of calcium antagonists]. Wiener medizinische Wochenschrift (1946). 1993:143(19-20):490-500 [PubMed PMID: 8135031]
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension (Dallas, Tex. : 1979). 2018 Jun:71(6):e13-e115. doi: 10.1161/HYP.0000000000000065. Epub 2017 Nov 13 [PubMed PMID: 29133356]Level 1 (high-level) evidence
Tajani AH, Nesbitt SD. Gingival hyperplasia in a patient with hypertension. Journal of clinical hypertension (Greenwich, Conn.). 2008 Nov:10(11):863-5. doi: 10.1111/j.1751-7176.2008.00036.x. Epub [PubMed PMID: 19128276]
Ikemura N, Yamaori S, Kobayashi C, Kamijo S, Murayama N, Yamazaki H, Ohmori S. Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. Chemico-biological interactions. 2019 Jun 1:306():1-9. doi: 10.1016/j.cbi.2019.04.005. Epub 2019 Apr 6 [PubMed PMID: 30965050]
Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2004:4(5):281-97 [PubMed PMID: 15449971]
St-Onge M, Dubé PA, Gosselin S, Guimont C, Godwin J, Archambault PM, Chauny JM, Frenette AJ, Darveau M, Le Sage N, Poitras J, Provencher J, Juurlink DN, Blais R. Treatment for calcium channel blocker poisoning: a systematic review. Clinical toxicology (Philadelphia, Pa.). 2014 Nov:52(9):926-44. doi: 10.3109/15563650.2014.965827. Epub 2014 Oct 6 [PubMed PMID: 25283255]Level 1 (high-level) evidence
WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 Oct 15:128(16):e240-327. doi: 10.1161/CIR.0b013e31829e8776. Epub 2013 Jun 5 [PubMed PMID: 23741058]Level 3 (low-level) evidence
. Nisoldipine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:(): [PubMed PMID: 31643685]
White WB, Saunders E, Noveck RJ, Ferdinand K. Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension. American journal of hypertension. 2003 Sep:16(9 Pt 1):739-45 [PubMed PMID: 12944032]Level 2 (mid-level) evidence
Lenz TL, Wurdeman RL, Hilleman DE. Comparison of 24-hour blood pressure profiles in patients with hypertension who were switched from amlodipine to nisoldipine. Pharmacotherapy. 2001 Aug:21(8):898-903 [PubMed PMID: 11718496]
Wachowiak R, Strach B, Lopatka P. [Toxicological analysis of selected 1,4-dihydropyridine calcium channel blockers in the diagnosis of intoxications]. Archiwum medycyny sadowej i kryminologii. 2005 Jan-Mar:55(1):47-54 [PubMed PMID: 15984121]
El Maghraby GM, Elsergany RN. Fast disintegrating tablets of nisoldipine for intra-oral administration. Pharmaceutical development and technology. 2014 Sep:19(6):641-50. doi: 10.3109/10837450.2013.813543. Epub 2013 Jul 10 [PubMed PMID: 23841582]